Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22138141 | 0.90 | KMT2A (0.36) | KMT2ACYP1A2CYP2C19MEN1 | |
| SCHEMBL20988715 | 0.88 | KMT2A (0.35) | KMT2ACYP1A2CYP2C19MEN1NPC1 | |
| SCHEMBL22209541 | 0.87 | CYP1A2 (0.33) | KMT2ACYP1A2CYP2C19 | |
| SCHEMBL19734913 | 0.85 | CYP1A2 (0.33) | KMT2ACYP1A2CYP2C19KDM4ERAB9A | |
| SCHEMBL19708674 | 0.82 | CYP1A2 (0.31) | KMT2ACYP1A2CYP2C19 | |
| SCHEMBL24379650 | 0.81 | CYP1A2 (0.33) | KMT2ACYP1A2CYP2C19 | |
| SCHEMBL21093199 | 0.70 | CYP19A1 (0.33) | — | |
| SCHEMBL24333892 | 0.69 | — | — | |
| SCHEMBL14022378 | 0.68 | KMT2A (0.49) | KMT2ACYP1A2CYP2C19MEN1NPC1 | |
| SCHEMBL20118277 | 0.68 | KMT2A (0.35) | KMT2ACYP1A2CYP2C19MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210353781-A1 | SURFACE-MODIFIED CELLS, METHODS OF MAKING AND USING | UNITED STATES GOVERNMENT | 2021-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353781-A1 | SURFACE-MODIFIED CELLS, METHODS OF MAKING AND USING | CD4, EPCAM, CD2 | KMT2A 2158/4885CYP1A2 4884/4885CYP2C19 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.